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Abnormalities of embryonic patterning are hypothesized to underlie many common congenital malformations in humans including
congenital heart defects (CHDs), left-right disturbances (L-R) or laterality, and holoprosencephaly (HPE). Studies in model organisms
suggest that Nodal-like factors provide instructions for key aspects of body axis and germ layer patterning; however, the complex genet-
ics of pathogenic gene variant(s) in humans are poorly understood. Here we report our studies of FOXH1, CFC1, and SMAD2 and sum-
marize our mutational analysis of three additional components in the human NODAL-signaling pathway: NODAL, GDF1, and TDGF1.
We identify functionally abnormal gene products throughout the pathway that are clearly associated with CHD, laterality, and HPE. Ab-
normal gene products are most commonly detected in patients within a narrow spectrum of isolated conotruncal heart defects (mini-
mum 5%–10% of subjects), and far less commonly in isolated laterality or HPE patients (~1% for each). The difference in the mutation
incidence between these groups is highly signiﬁcant. We show that apparent gene dosage discrepancies between humans and model
organisms can be reconciled by considering a broader combination of sequence variants. Our studies conﬁrm that (1) the genetic vul-
nerabilities inferred frommodel organisms with defects in Nodal signaling are indeed analogous to humans; (2) themolecular analysis of
an entire signaling pathway is more complete and robust than that of individual genes and presages future studies by whole-genome
analysis; and (3) a functional genomics approach is essential to fully appreciate the complex genetic interactions necessary to produce
these effects in humans.Introduction
Holoprosencephaly (HPE) is the most common structural
malformation of the embryonic brain (observed in 1 in
250 human conceptuses).1–4 Its etiology rests in the failure
to appropriately specify ventral or dorsal prosencephalon
midline structures that, in turn, leads to varying degrees
of incomplete separation of the forebrain into discrete
hemispheres.1,2,5–8 A very broad range of malformations
of the brain and face comprise the HPE clinical spectrum.
In contrast, most examples of targeted disruption of genes
in mice or other model systems produce only the single-
eye (i.e., cyclopic) extreme in homozygous null genotypes,
whereas animals heterozygous for these null alleles are typ-
ically normal (reviewed in 9). Unlike this cyclopic extreme,
HPE in humans is generally considered to be multifacto-
rial, with numerous genes and environmental factors
thought to interact in its causation.5,7,8 Empirical evidence
for such a multifactorial etiology has been difﬁcult to es-
tablish because of the multiplicity of causative agents
and limitations of our understanding of precisely how
the genes and environmental causes can interact5,7,8 (E.R.
and M.M., unpublished data). Nevertheless, rare examples
of mutations in more than one gene have been described
and tend to support this multiple-hit hypothesis5
(reviewed in 7).18 The American Journal of Human Genetics 83, 18–29, July 2008Central to our present understanding of HPE pathogen-
esis is a failure in the patterning of the midline resulting
from either (1) defects in the formation or positioning of
the midline per se (e.g., features that are dependent on
NODAL10 [MIM 601265] factors), (2) defects in the signal-
ing from the ventral-most aspect of the axial midline (the
prechordal plate signals, such as secreted SHH [MIM
600725], culminating in the activation of its transcription
factor GLI2 [MIM 165230]), or (3) the inability of the fu-
ture forebrain cells to appropriately respond to such signals
(e.g., neuroectodermal SIX3 [MIM 603714], ZIC2 [MIM
603073], and TGIF [MIM 602630] haploinsufﬁciency). Al-
though there is excellent evidence for the roles of each of
these genes in producing HPE,1,2,5,7–9 there is limited evi-
dence for more than one gene contributing to HPE in
any individual clinical case.
Most cases of HPE appear to be sporadic, because parents
of affected individuals are usually phenotypically normal.
In addition, genetic counseling is typically extremely difﬁ-
cult given that only 20%–25% of cases can be attributed to
a detectable abnormality in any one of the known HPE
genes.7,8 Studies of HPE families, although less common,
usually support apparent autosomal-dominant transmis-
sion of a principal susceptibility gene. However, it has
long been recognized that the penetrance is reduced and
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a single family transmitting a known HPE gene vari-
ant.1,5,7,8 A complete understanding of HPE etiology is elu-
sive; many of these known gene mutations are likely to be
necessary (yet not entirely sufﬁcient) to produce an effect.
The multiple-hit hypothesis5 argues that the readily de-
tectable mutations in HPE genes observed in patients rep-
resent only one of several discrete steps needed to produce
these pathological disturbances. However, it has been difﬁ-
cult to demonstrate the gene-gene or gene-environmental
interactions considered essential to produce this complex
syndrome given the limitations imposed by its inherent
genetic heterogeneity and low frequency of any given pri-
vate mutation. For most HPE patients, only a single hetero-
zygous change is detectable through routine molecular
screening, and systematic attempts have only rarely identi-
ﬁed mutations in more than one HPE gene in a single
patient5 (E.R. and M.M., unpublished data).
Heterotaxy disorders (such as discordant or mirror-image
development of intrinsically asymmetric internal or-
gans11,12 and/or isolated congenital heart defects13–15) are
also thought to be multifactorial conditions ultimately
linked to the integrity of the axial midline and/or L-R pat-
terning signals. These conditions also comprise a clinical
spectrum and are considered equally complex in the inter-
play of genetic and environmental factors underlying their
causation. For example, X-linked heterotaxy (HTX [MIM
306955]) occurs in males resulting from hemizygosity for
a loss-of-function allele of the zinc-ﬁnger transcription
factor ZIC3 (MIM 300265).16 Interestingly, males can man-
ifest the discordant internal organ positioning typical for
the heterotaxy syndrome or can instead display isolated
congenital heart defects as the sole clinicalmanifestation.17
Both phenotypes are associated with similar degrees of
functional impairment of the ZIC3 gene product,18 suggest-
ing that genetic or environmental modiﬁers act in concert
with these gene lesions. Like HPE, these malformations
are due to heterogeneous causes, most of which are pres-
ently unknown. However, in order for asymmetric organo-
genesis to proceed, there must be an elaboration of signals
that distinguish the left and right sides of the embryo; this
link with Nodal signaling is shared, along with the require-
ment for the axial midline, for preventing cyclopia.19,20
We selected the NODAL signaling pathway as a test case
for study because the principal genetic components of this
pathway are well understood (Figure 1) and have been
clearly implicated in clinically relevant dysmorphologies
in model systems. To gain insight into the frequency and
types of combinations of alterations evident in our patient
groups, we performed a detailed molecular survey of
NODAL pathway genes. Our current and previous studies
are summarized in Figure 2. To assess the multiple-hit
hypothesis5,21,22 in the context of NODAL signaling, we
examined genomes of individuals with CHD, laterality,
and HPE, as well as controls, for mutations in the following
core NODAL signaling components: NODAL, GDF1 (MIM
602880), CFC1 (MIM 605194; GenBank NM_032545),
TDGF1 (MIM 187395; GenBank NM_003212), FOXH1(MIM 603621; GenBank NM_003923), and SMAD2 (MIM
601366; GenBank NM_001003652). We then developed
strategies to assess the functional consequences of these se-
quence variations, exploiting the zebraﬁsh as a biosensor
amenable to rapid functional analysis.
Our studies now demonstrate that (1) although muta-
tions in individual NODAL pathway genes are uncommon,
when considered collectively these pathway lesions are not
rare and are slightly more common than well-described ge-
netic changes such as chromosome 22q11.2 deletion syn-
drome (MIM 611867);23,24 (2) combinations of gene le-
sions are likely the determinative factor of phenotypic
outcome, with speciﬁc phenotypes being more prevalent
than others; (3) modiﬁer genes within a signaling pathway
can account for a substantial proportion of reduced path-
way activity and are quite common in human populations
(E.R. and M.M., unpublished data); and (4) common
Figure 1. The Essential Components of Nodal Signaling
TGF-b proteins are synthesized as pre-pro-proteins requiring cleav-
age of the signal peptide (black) and prodomain (orange) prior to
dimerization of active ligand (red diamonds). Cells responsive to
Nodal-like ligands display Type I/II Activin receptors on their cell
surface with coreceptors of the EGF-CFC family required for certain
ligands, such as Nodal and Gdf1. The Lefty proteins (yellow) inter-
fere with mature ligand binding to receptors. Ligand binding trig-
gers transphosphorlyation of type I receptors by the type II recep-
tor serine-threonine kinase domain. Receptor-regulated R-Smads
(green) become activated on the inner surface of the cell membrane
through phosphorylation by type I receptors. Activated Smad com-
plexes include two R-Smads and the common Smad4 (black) that
translocate into the nucleus to affect gene expression. Target genes
typically contain binding sites for Smads and cofactors such as
FoxH1 (red triangle) to achieve tissue-specific gene expression.
Human mutations have been previously described in LEFTYA
(MIM þ601877), LEFTYB (MIM *603037), ACVR2B (MIM þ602730)
(see reference 12 for review), CFC1 (MIM *605194),27,28 TDGF1
(MIM þ187395),25 and GDF1 (MIM þ602880).39The American Journal of Human Genetics 83, 18–29, July 2008 19
Figure 2. A Summary of Previously
Studied Genes and Patient Groups Are
Presented to Help Clarify the Presenta-
tion and Analysis
Only ‘‘typical mutations’’ (i.e., disease var-
iant alleles, circle; or unique alleles,
square) are shown for each study. The com-
mon polymorphisms and synonymous cod-
ing region changes (omitted here) are
not likely to have a distortion in allele fre-
quency among groups; however, this needs
to be rigorously tested. Furthermore, only
significant (red ¼ <50% function) or
mild (orange ¼ 50%–99%) functional
impairments are considered. Previously de-
termined published mutations are shown,
but do not contribute to the tabulations
in Table 1. The Baylor study yields similar
conclusions but are tabulated separately
because we were blinded by the study
design to their phenotypes.modiﬁers can be overlooked unless functional studies are
systematically performed.
Material and Methods
Study Population
Our pilot consortium study consists of 375 unrelated individuals
prospectively ascertained at several urban centers with a wide spec-
trumof congenital cardiovascularmalformations (essentially asdia-
grammed in Figure 2). CHD cases including transposition of the
great arteries (TGA), tetralogy of Fallot (TOF), double outlet right
ventricle (DORV), atrial septal defect (ASD), commonatrioventricu-
lar canal (CAVC), and interrupted aortic arch (IAA) were studied.
Coded affected proband DNA samples were obtained from three
consortium centers (Children’s Hospital of Philadelphia, Philadel-
phia,PA;BaylorCollegeofMedicine,Houston, TX; andYaleUniver-
sity School of Medicine, New Haven, CT) according to the guide-
lines of the Institutional Review Boards (IRBs) of each institution
and with the supervisory approval of the IRB of the NHGRI/NIH
for patients with cardiovascular anomalies or HPE. All patient sam-
pleshadbeencollectedpurely for researchpurposes andno consent
had been obtained to return results of unknown signiﬁcance to the
subjects. None of the patients with cardiovascular anomalies were
seen at theNIH. Therefore, parents and siblingswerenot consented
to participate in our NIH consortium study because of the prelimi-
nary nature of the research, to maintain conﬁdentiality, and be-
cause the links to patient identiﬁers were retained by the host insti-
tutions where their care was provided. We routinely screened
between 300 and 500 unrelated patients with HPE (depending on
thegene).Thesepatientsandtheir familiesparticipated ina separate
research protocol approved by the IRB of the NHGRI/NIH. In addi-
tion, we studied at least 125 unrelated individual normal controls
obtained as ethnically matched anonymous samples from the Cor-
iell Institute for Medical Research. A separate set of samples was
studied forNODAL andFOXH1 variations by independentmethods
(with funding by the research team at Baylor College of Medicine;
J.A.T. and J.W.B., unpublished data). In these cases (cited in Figures
2–5), only information regarding the nature of the mutation and20 The American Journal of Human Genetics 83, 18–29, July 2008general phenotype was shared in order to allow functional analysis
in zebraﬁsh to complement their cell-based assays.
PCR Ampliﬁcation, Mutation Screening, and DNA
Sequencing
Oligo 4.1 was used to design primers for the relevant exons or reg-
ulatory elements (see Table S2 available online). Ampliﬁcation of
human genomic DNA and screening was performed essentially
as previously described in reference 25.
Site-Directed Mutagenesis and Construct Design
The cDNA-derived coding regions of the NODAL (H165 and E203
variants) or FOXH1 geneswere directionally cloned into pcDNA3.1
by standard methods. Site-directed mutagenesis was performed ei-
ther with a minor modiﬁcation of the Transformer kit (Promega,
WI) by Transponics (York, PA) or by using the GeneTailer (InVitro-
gen) kit to introduce the human sequence variations.
Zebraﬁsh FOXH1 Rescue Assays
Human FOXH1 alleles were prepared in two sets of pcDNA3.1-de-
rived vectors: OV and NV. OV lacked the expected translational
stop, such that the predicted protein product included an ad-
ditional COOH-terminal sequence (DYKDDDKWNSQKPNSA
DIQHSGGRSTGPV) that includes a FLAG-tag (underlined) and
an additional 22 amino acid residues derived from the pcDNA3.1
vector. The X366Q allele includes two additional codons (GS) be-
fore terminating within the 30UTR of the genomic sequence. Plas-
mids were linearized with EcoRI and the sense strand was synthe-
sized with the SP6 Message Machine kit (Ambion) followed by
the synthetic addition of polyA. Wild-type (wt) or variant FOXH1
mRNAs were comicroinjected into zebraﬁsh embryos with 4 ng of
an antisensemorpholinooligonucleotide [MO] targeting the trans-
lational start site of zebraﬁsh foxh1, as previously described (ATG1
MO26). Injected embryos were allowed to develop to the pharyng-
ula stage (28–32 hr after fertilization) and scored as wt, dead, or be-
longing to one of the following classes. Class I weremildly affected
with crooked tails; Class II had more severe defects including tails
shorter than trunks; Class III had even shorter tails and/or were im-
motile; andClass IVwerehighlydeformed and conﬁned to the tops
of yolks. In thisway, a signature phenotypic spectrumwas assigned
to each group of treated embryos. The activity of a given allele was
determined from its ability to ameliorate the phenotypic spectrum
associated with loss of endogenous zebraﬁsh FoxH1 (MO alone),
compared to the amelioration resulting from coinjection of wild-
typehuman FOXH1mRNA (MOþ FOXH1). Activitywas quantiﬁed
as follows: aphenotypic index (PI)wasdetermined for eachgroupof
injected embryos by assigning a value to each embryo of each phe-
notype (wt¼ 4; Class I ¼ 3; Class II ¼ 2; Class III¼ 1; Class IV ¼ 0),
multiplying thenumberof embryos ineachclassby thecorrespond-
ing assignedvalue, anddividing the sumby the total number of em-
bryos. Activity relative to wt FOXH1 was determined as follows.
First, PIs were background adjusted by subtracting the PI associated
with a negative control injection (MO only) that was performed inparallel for each data point, averaged (for multiple experiments),
and divided by the average of similarly adjusted PIs for wt FOXH1.
Amathematical description of these steps is: wild-type-adjusted ac-
tivity (WTAA) of FOXH1EXP¼Ave (PIEXP PIMO)/Ave (PIWTFOXH1
PIMO). For photography, embryos weremounted in 2%methyl-cel-
lulose and imaged on a Leica MZ16 dissecting microscope.
Results
Heterozygous Mutations Can Be Detected in Most
Nodal Pathway Components
To assess the distribution of Nodal pathway mutations
among affected patients and controls, we screened forThe American Journal of Human Genetics 83, 18–29, July 2008 21
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mutations in the NODAL, GDF1, CFC1, TDGF1, FOXH1,
and SMAD2 genes in patients with CHD, laterality, HPE,
and controls. A tabulation of the sequence variations de-
tected in this summary analysis is shown in Table 1 (for
a more complete tabulation from this study, see Figures
3–5; the description ofNODALmutations will be presented
elsewhere; E.R. and M.M., unpublished data). Except for
SMAD2, we could ﬁnd potentially disruptive sequence al-
terations in each of the pathway components examined,
the most being within NODAL, CFC1, and FOXH1. Assays
Table 1. Summary of Abnormal Alleles by Phenotype
Phenotypic Distributiona Severe (0%–50%) Mild (50%–99%)
CHDb
TGA 3 0
DORV 2 2
TOF 13 4
AVC 1 1
IAA 0 0
TA 1 0
Unspecified 0 2
total: 20 total: 9
percent: (5.3%) percent: (2.4%)
Lateralityc total: 4 total: 4
percent: (~1%) percent: (~1%)
HPEd total: 4 total: 2
percent (~1%) percent (<1%)
a CHD, congenital heart defects; TGA, transposition of the great arteries (n
¼ 62); DORV, double outlet right ventricle (n¼ 23); TOF, tetralogy of Fallot
(n ¼ 121); AVC, atrioventricular canal (n ¼ 27); IAA, interrupted aortic
arch (n ¼ 19); TA, truncus arteriosus (n ¼ 15); unspecified (n ¼ 108);
HPE, holoprosencephaly (n ¼ ~4005 100). These figures represent mini-
mum estimates and include only unpublished prototypical ‘‘mutations’’
among the 375 patients in this study (i.e., disease variations or unique mu-
tations) where interpretable functional studies have been performed. Syn-
onymous changes, noncoding variations, and common polymorphisms are
not included; these syn and cp variants are not known to be more highly
enriched among patient versus control groups. Note the percentage of cases
with defective NODAL pathway factors by particular anatomic type is even
higher (e.g., 17/121 ¼ 0.14 for defective function in the TOF subgroup, or
4/23¼ 0.17 for the DORV subgroup, or 3/62¼ 0.048 for the TGA subgroup;
compared with 0/125 for the controls).
b n ¼ 375 (as outlined in Figure 2).
c n ¼ 388 cases studied at Baylor (J.W.B. and J.A.T., unpublished data).
d n ¼ 400 (approximate).to test the signiﬁcance of these variants were developed
and performed.
Because we were interested in potential gene-gene inter-
actions, the same patients (derived from multiple cohorts
and controls) were typically screened for sequence varia-
tions in the entire gene set. Sequence variations were fur-
ther annotated as signiﬁcant loss of function (<50% of
normal activity, indicated in red in Figures 3–5 and related
ﬁgures), mild loss of function (50%–99% normal activity,
indicated in orange), normal activity (black), or not yet re-
liably tested (blue). Contrary to our initial expectations of
multifactorial or typical digenic inheritance, each proband
can be usually assigned to a principal change in a single
gene. There are, however, some notable exceptions to
this pattern, especially with respect to putative NODAL
modiﬁers (see below). Our functional analysis of NODAL
H165R suggested to us that this common variant has less
than 50% normal activity in various assay systems (E.R.
and M.M., unpublished data). Our working hypothesis re-
lated to this ﬁnding is that such variants are neutral to se-
lection pressure because they are still well above the
threshold level of 50% of Nodal activity seen in healthy
normal mice with a single Nodal null allele (see Tables S3
and S4). Instead, they serve as modiﬁers of mutations
that occur in other NODAL pathway components with
which they normally must interact. And being so com-
mon, they become essential in the estimation of the im-
pact of mutations among these or related genes.
As can be seen in Figures 3–5, some of themore common
changes were synonymous coding region variations. Func-
tional studies were not undertaken for these sequence var-
iants because the ultimate protein structure would not
be affected. Similarly, nonsynonymous coding region
changes seen in normal controls were generally disre-
garded as common polymorphisms, a common practice
in human genetic studies. In retrospect, this initial bias de-
served re-examination (see below). Nonsynonymous cod-
ing region changes observed in multiple probands (but
provisionally not normal controls) and yet potentially im-
plicated in different phenotypes among affected individ-
uals comprised a third class we have termed disease variant
alleles. Finally, we observed very rare variations seen
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individuals, which we shall refer to as unique alleles. In our
previous studies with HPE, virtually all of the hundreds of
disease-associated variants have been unique alleles.
Searches of public databases (e.g., dbSNP) were performed
to identify any known polymorphisms within the geno-
mic regions examined; these are indicated by their refer-
ence numbers in Figures 3–5.
Functionally Abnormal Alleles Occur Most Frequently
in Conotruncal Defects
Deleterious sequence variations were seen across most
genes and all phenotypes examined with no evidence of
an absolute genotype-phenotype correlation. However,
mutations were detected far more frequently in patients
with congenital heart defects (especially tetralogy of Fallot
and related conotruncal malformations) than in laterality
patients or those with HPE (Table 1). The population
groups were of similar size and ethnicity, so this ﬁnding
is highly signiﬁcant (p < 0.001). This spectrum of malfor-
mation may reﬂect the cumulative genetic impairment
required to produce each phenotype and also might reﬂect
only those select genetic combinations compatible with
postnatal survival (see Discussion).
Sequence Variation in the EGF-CFC Proteins
Loss-of-function mutations in CFC1 (G174 del1 and
R112C) were originally detected in patients with laterality
defects27 and subsequently also identiﬁed in patients with
conotruncal defects (G174 del1 and a unique splice site
duplication).28 In addition, we identiﬁed a common poly-
morphism (P75P) R78W that was more prevalent in
subjects of African-American origin and which was hy-
pomorphic in functional studies.27–29 Similarly, we had
detected a single functionally abnormal allele (TDGF1
P125L) in HPE patients.25 Here we present the results of
screening for CFC1 and TDGF1 alterations in additional
patients with isolated congenital heart defects. These
newly detected sequence variations are summarized in Fig-
ure 6. Although we did not perform any new functional as-
says for these CFC1 and TDGF1 alleles, functional data is
available for some of the disease variant alleles and com-
mon polymorphisms that we re-isolated. For instance,
G174 del1 is a loss-of-function disease variant allele de-
tected here in a TOF proband as well as previously in
DORV and three different probands with laterality. We
also observed another disease variant allele, a mutation
in the invariant splice donor sequence (IVS4þ2T/C),
seen in four unrelated subjects and predicting a truncation
of the CFC1 protein with an incomplete CFC domain. Ad-
ditional intronic and 50UTR variations were detected in
this new population; however, these have not yet been
tested for their potential effects. Several more disease vari-
ant alleles (such as F162L and A145T) and unique alleles
(P193L, E210K, R211Q, and P217R) were also detected,
but their signiﬁcance is presently unknown. However,
the four unique alleles might not affect bioactivity, because
they alter only human-speciﬁc amino acids in the carboxyl24 The American Journal of Human Genetics 83, 18–29, July 2008terminus that are dispensable in other organisms. Finally,
we note that Ozcelick et al. also detected the A145T vari-
ant, both in normal controls and in patients with cardiac
malformations, and concluded that this variant was
unlikely to contribute to disease.30 However, because the
distinction between common polymorphisms and disease
variant alleles is empiric and given our own documented
examples of functionally abnormal common polymor-
phisms (e.g., (P75P) R78W above), a deﬁnitive assignment
cannot be made without further studies. For example, we
observed a patient that has the hypomorphic common
polymorphism (P75P) R78W in CFC1 as well as a unique
FOXH1 allele (V112M, described below) with diminished
function, suggesting that genetic interactions might occur
in some individuals with variations in more than one gene
(see Figures 3–5).
We observed limited sequence variation in the human
TDGF1 gene in the cardiac samples in this study. Neverthe-
less, it is noteworthy that the functionally abnormal P125L
variant we found in a TOF patient was previously detected
in an individual with HPE.25 These phenotypes are sufﬁ-
ciently distinct, so this observation suggests that either
loss of function of a single allele of TDGF1 is an incidental
ﬁnding, or, as we consider to be more likely, that there are
genetic or environmental modiﬁers that determine the
expressivity of this alteration. Although the signiﬁcance
of TDGF1 V110L is also unknown, it is reasonable to con-
sider that functional studies would be informative and, fur-
thermore, that even common polymorphisms such as the
highly conserved R111G variant seen in normal controls
should be examined.
Functional Analysis of Variants in FOXH1
FoxH1 depends on the presence of phosphorylated Smad
proteins to exhibit the DNA binding associated with bio-
logical activity. Interestingly, we observed that overexpres-
sion of human FOXH1 mRNA in zebraﬁsh could partially
rescue phenotypic dysmorphologies associated with the
loss of endogenous zebraﬁsh Foxh1 that we depleted by
injection of an antisense morpholino oligonucleotide tar-
geting translation of the zebraﬁsh mRNA (but not human
FOXH1 constructs).26 The degree of bioactivity of human
FOXH1 variants could then be estimated bymorphological
scoring of clutches of embryos coinjected with the anti-
sense morpholino oligonucleotide. Four phenotypic clas-
ses could be reliably distinguished from each other and
from uninjected control embryos (Figure 7) that served
to estimate the bioactivity of each variant compared to
the wild-type gene (Figures S1A–S1D and Table S1).
FOXH1 is a transcription factor that has two principal
domains, namely, the forkhead domain necessary for bind-
ing DNA and a C-terminal domain that interacts with
Smad proteins. This Smad interaction domain (SID) is fur-
ther deﬁned by submotifs FM1 and FM2 and a core Smad
interaction motif shared by other R-Smad cofactors31,32
(Figure 8). The extreme C terminus following the SIM
tolerates extensive genetic variation without affecting
Figure 6. Multiple Sequence Alignment of EGF-CFC Proteins
Missense changes detected in human TDGF1 and CFC1 are shown within the context of an alignment of related proteins. Loss-of-function
changes are in red (missense, solid;25,27,28 coding region frameshift,27,28 triangle without fill; splice alteration frameshift, inverted tri-
angle without fill), hypomorphic changes are in orange,29 residues not analyzed are in blue,30 and those with normal activity are in black.function in our assays. Three frameshift variants in this
segment had little effect on biological activity (residues
352 to 365). This preliminary analysis of the extreme C ter-
minus following the SIM suggests that most of the genetic
variability seen in this segment of the protein can probably
be disregarded.
We detected three variations in the forkhead domain
that appear to affect biological function: P35L, V112M,
and the common variant S113T. The latter change is yet
another interesting example of a common polymorphism
that is seen in HPE as well as TGA and TOF. Although our
preliminary ﬁnding that S113T reduces activity by 20%
needs to be conﬁrmed, we note the case where S113T/
S346G in FOXH1 is detected in the same TOF patient
with the nonsynonymous R211Q variant in CFC1. Indeed,
it seems likely that common polymorphisms are capable of
interacting with a variety of other genes. We chose not toexamine the T125S variant because it was frequently pres-
ent in normal controls, which biased us against it at the
time of the study. However, this amino acid is conserved
and could indeed be functionally relevant (e.g., another
example of a deleterious common polymorphism).
There is a striking distribution of variants with dimin-
ished function found in the key FM1 and SIM motifs.
P278T occurs in the core FM1 motif and completely elimi-
nates detectable activity; this HPE patient also has addi-
tional variations including H269Q and S364I. A com-
pound allele with all three changes lacks all detectable
activity. The variant L282S is only mildly abnormal and
was identiﬁed in a proband with HPE in the homozygous
state in cis with the ostensibly benign L365M change.
Signiﬁcantly, when this compound allele was tested, we
detected synergy between these changes with a reduction
of bioactivity to 50% (i.e., mild to severe shift in activity).The American Journal of Human Genetics 83, 18–29, July 2008 25
P304T is a normal allele, whereas the patient with the hy-
pomorphic S339G change in the SIM domain has TOF and
a second change in CFC1 (IVS4þ2T/C). The core SIM is
deﬁned by a consensus sequence (PPNK) and adjacent res-
idues, and mutations in this region lead to signiﬁcant loss
of activity in cases of CHD (D328E), HPE (F331V), and
TOF (P336L). Although additional detailed studies of the
extreme C terminus are indicated, we note that D350G is
another example of a disease variant detected in HPE and
TOF that is a mild hypomorph.
Taken together with the functional analysis of other
genes within the pathway, these variants in FOXH1 have
the potential to interact signiﬁcantly with variations in
other genes both common and uncommon. In the absence
of another transcription factor to compensate for reduced
FOXH1 activity, even small reductions in biological activ-
ity can have signiﬁcant effects. Furthermore, genes that
cooperate with FOXH1 to activate target genes may be
inﬂuenced by diminished FOXH1 function. In fact,
NKX2.5 (MIM 600584), whose murine ortholog has been
shown to act interact with murine Foxh1 in heart forma-
tion, has been independently identiﬁed as a potential
cause of TOF and related cardiac malformations by the
identiﬁcation of mutations in this gene.33,34 It will be in-
teresting to expand the evaluation of the role of FOXH1
in human disease to include additional transcriptional
factor networks.
Discussion
One of the central goals of this study was to determine the
frequency and composition of sequence variations in the
NODAL pathway contributing to human disease(s).We hy-
pothesized that if the conditions under study were due to
typical digenic inheritance, then a consistent pattern of
mutations inmore than one gene would be readily demon-
strable. In fact, we detected functionally signiﬁcant muta-
tions inmore than one unique or disease variant gene only
Figure 7. Human FOXH1 Rescue Assay Phenotypes
Embryos were classified into four degrees of phenotypic manifesta-
tions ranging from mild ventral curvature (Class I) to severe embry-
onic arrest (Class IV). Experimental clutches of embryoswere individ-
ually scored and a phenotypic index calculated for each experiment.26 The American Journal of Human Genetics 83, 18–29, July 2008rarely; as such, if one limits one’s view to functionally com-
promised alleles in these two classes, our hypothesis does
not bear out. But if one considers that common polymor-
phisms with reduced bioactivity like NODAL H165R and
CFC1 (P75)R78W could act as modiﬁers, a different picture
emerges (see Tables S3 and S4). In these cases, genetic inter-
actions among multiple alleles would need to be consid-
ered: one or two copies of the functionally impaired com-
mon polymorphism and a third, less common pathway
variant (or one or two copies of another functionally im-
paired common polymorphism). Because the degree of
functional impairment ranged from severe to mild for
any particular gene, we believe that the cumulative impair-
ment of pathway activity may be amore important consid-
eration than the contribution of any individual gene. Even
making conservative assumptions regarding how genes
within a pathway interact allows for a considerable closure
in the gap between the genetic examples extrapolated
from animal models to humans (see Tables S3 and S4 for
illustrative examples).
In humans, the most common genetic alteration to date
affecting conotruncal development is the consequence of
the common deletion seen in 22q11.2/DiGeorge syn-
drome in approximately 5% of cases.23,24 Collectively,
our study suggests that NODAL pathway defects are detect-
able at a slightly higher frequency (5%–10%). Perhaps even
more signiﬁcantly, plausible biochemical interactions have
been proposed between the Nodal pathway and other key
genes affecting conotruncal development including TBX1
(implicated in 22q11.2 deletion syndrome), TBX5 (impli-
cated in Holt-Oram syndrome [MIM 142900]) and
NKX2.5 (implicated in TOF).13–15,33–35 As such, meaning-
ful synergies may exist between defective TBX1, TBX5, or
NKX2.5 alleles and the defective Nodal pathway alleles
we have described here. Therefore, although genetic
heterogeneity will likely continue to confound genetic
counseling efforts for patients with CHD, there remains
a distinct promise of a more fully integrated genomics ap-
proach in the future. As technical and cost challenges are
being addressed to solve whole-genome sequencing for
patients, there are many reasons to argue that this will
be essential to detecting the gene-gene interactions of
common and rare variations that affect heart and brain
development.
Studies in model organisms have suggested that defec-
tive Nodal signaling is a major etiological cause of cyclopic
phenotypes. Our systematic analysis of the human
NODAL signaling components at the mutational level
would suggest that defective signaling of this pathway con-
tributes to only a minority of HPE cases. The relative scar-
city of prototypical mutations in the NODAL signaling
pathway components in HPE suggest that some of the ge-
netic combinations resulting in cyclopia in mice (such as
Nodal; Smad236) are not common representative models
of human cases of disease, at least in live-born infants.
Unlike somatic mutations in SMAD2 detected in cancer
syndromes, inherited defects in SMAD2 (and potentially
Figure 8. Alignment of Zebrafish, Xenopus, Murine, and Human FOXH1 Proteins
Identical residues are shown in blue, and similar residues are shown in yellow. Considerable sequence identity is seen in known functional
domains, including the DNA-binding forkhead domain and the SMAD interaction domain. The SMAD interaction domain contains three
motifs: FM1, FM2, and the core Smad-interaction motif (SIM).31,32 Note that the extreme C terminus after the SIM is poorly conserved,
but it contains a significant fraction of detectable variations of both patients and controls. Most of these variants are inadequately stud-
ied to draw definitive conclusions (scored as blue and, therefore, do not contribute to the tabulations in Table 1). Mutations are anno-
tated by amino acid position and colored as in previous figures (red, less than 50%; orange, 50%–99%; blue, not adequately tested; black,
normal activity; frameshift, blue or black with no fill).SMAD3) might be selected against during fetal develop-
ment because of the several TGFb ligands that utilize these
transcription factors to control the expression of target
genes.
Laboratory strains of mice are particularly powerful for
genetic analysis precisely because their inherent genetic di-
versity has beenminimized by deliberate inbreeding. Inter-
esting differences in phenotypes are observed when identi-
cal gene-targeted alleles are crossed into different strain
backgrounds.37,38 Such phenotypic differences are com-
monly attributed to strain-speciﬁcmodiﬁers. There is every
reason to suspect that gene modiﬁers play an even more
signiﬁcant role in human populations.9 We propose that
the apparent gulf between mouse and human phenotypes
are not nearly as irreconcilable as it seems (because identi-
cal gene-gene interaction rules are used to compare mouse
models and human patients in Table S3 versus S4). Consid-
eration of the combinations of deleterious alterations indifferent genes results in estimations of activity that are
very close to the levels producing phenotypic effects in
the mouse. This would be true even without considering
the potential contributions of additional pathway variant
alleles in this or parallel pathways.
Clearly, this study does not attempt to incorporate the
effects of all known factors relevant to NODAL signaling.
Future studies would be needed to systematically examine
the extent of sequence variation in an expanded set of
genes either directly involved in the processing and gener-
ation of ligands, or associated with tissue distribution and
receptor binding, partially redundant factors (e.g., SMAD3
or GDF3), downstream target genes, and transcriptional
coregulators with the aim of functionally characterizing
all types of nonsynonymous variations including those
also present in normal control populations. By identifying
likely instances of complex interactions contributing to
human disease, this study underscores the importance ofThe American Journal of Human Genetics 83, 18–29, July 2008 27
functional genomic approaches for understanding these
disorders.
Supplemental Data
One ﬁgure and three tables are available at http://www.ajhg.org/.
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